M3 Receptor Inhibitory Peptides for Selective Skin Modulation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing treatments for skin conditions mediated by muscarinic receptor M3 activity, such as excessive perspiration and inflammation, suffer from poor selectivity, leading to undesirable side effects due to the lack of subtype-selective ligands.
Innovation Solution
Development of novel peptides that inhibit M3 activation by interacting with intracellular regions of the receptor, specifically acting as antagonists to impair downstream signaling, with sequences ranging from 1 to 20 amino acids and modifications like alkyl carbonyl groups or salt formations.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If existing treatments for skin conditions mediated by muscarinic receptor M3 activity are used, then therapeutic effect is achieved, but selectivity is poor leading to undesirable side effects
Solution Approach 1:
The patent applies local quality by designing peptides with specific amino acid sequences (e.g., Seq ID no. 1: WMRL, Seq ID no. 6: RMYKMMAGMYLR) that confer selective affinity for M3 receptor intracellular regions. This localized molecular design enables the peptides to interact specifically with M3 receptor isoforms while minimizing cross-reactivity with other muscarinic receptor subtypes, thereby achieving therapeutic effects with reduced side effects
2Adaptability or versatility
If non-selective muscarinic antagonists are used to treat skin conditions, then broad receptor blockade is achieved, but subtype selectivity is lost causing systemic side effects
Solution Approach 1:
The patent segments the muscarinic receptor targeting approach by designing short peptides (1-20 amino acids) that specifically interact with intracellular regions of M3 receptor. This segmentation allows selective modulation of M3-mediated pathways (sweat secretion, inflammation, sebum production) without blocking other muscarinic receptor subtypes, thereby avoiding systemic side effects associated with broad antagonism
3Reliability
If peptides with higher M3 selectivity are developed, then targeted treatment is improved, but peptide sequence complexity increases
Solution Approach 1:
The patent extracts the essential M3-selective functional motif by identifying and isolating specific amino acid sequences (e.g., WMRL, RMYKMMAGMYLR) that confer M3 receptor selectivity. These minimal peptide sequences (1-20 amino acids) capture the critical binding elements needed for M3 interaction while eliminating unnecessary complexity, enabling straightforward synthesis and clinical application
Data Source
AI summary
Peptides able to inhibit the muscarinic receptor M3 activity and to products comprising such peptides, in particular pharmaceutical and cosmetic products useful for ameliorating skin conditions mediated by the muscarinic receptor M3 activity, such as excessive perspiration, inflammation, sebum production, and cell adhesion, motility, growth, differentiation and proliferation.